%0 Journal Article
%A Tian, Yu
%A Lin, Yi
%A Qu, Conghui
%A Arndt, Volker
%A Baurley, James W
%A Berndt, Sonja I
%A Bien, Stephanie A
%A Bishop, D Timothy
%A Brenner, Hermann
%A Buchanan, Daniel D
%A Budiarto, Arif
%A Campbell, Peter T
%A Carreras-Torres, Robert
%A Casey, Graham
%A Chan, Andrew T
%A Chen, Rui
%A Chen, Xuechen
%A Conti, David V
%A Díez-Obrero, Virginia
%A Dimou, Niki
%A Drew, David A
%A Figueiredo, Jane C
%A Gallinger, Steven
%A Giles, Graham G
%A Gruber, Stephen B
%A Gunter, Marc J
%A Harlid, Sophia
%A Harrison, Tabitha A
%A Hidaka, Akihisa
%A Hoffmeister, Michael
%A Huyghe, Jeroen R
%A Jenkins, Mark A
%A Jordahl, Kristina M
%A Joshi, Amit D
%A Keku, Temitope O
%A Kawaguchi, Eric
%A Kim, Andre E
%A Kundaje, Anshul
%A Larsson, Susanna C
%A Marchand, Loic Le
%A Lewinger, Juan Pablo
%A Li, Li
%A Moreno, Victor
%A Morrison, John
%A Murphy, Neil
%A Nan, Hongmei
%A Nassir, Rami
%A Newcomb, Polly A
%A Obón-Santacana, Mireia
%A Ogino, Shuji
%A Ose, Jennifer
%A Pardamean, Bens
%A Pellatt, Andrew J
%A Peoples, Anita R
%A Platz, Elizabeth A
%A Potter, John D
%A Prentice, Ross L
%A Rennert, Gad
%A Ruiz-Narvaez, Edward A
%A Sakoda, Lori C
%A Schoen, Robert E
%A Shcherbina, Anna
%A Stern, Mariana C
%A Su, Yu-Ru
%A Thibodeau, Stephen N
%A Thomas, Duncan C
%A Tsilidis, Konstantinos K
%A van Duijnhoven, Franzel J B
%A Van Guelpen, Bethany
%A Visvanathan, Kala
%A White, Emily
%A Wolk, Alicja
%A Woods, Michael O
%A Wu, Anna H
%A Peters, Ulrike
%A Gauderman, W James
%A Hsu, Li
%A Chang-Claude, Jenny
%T Genetic risk impacts the association of menopausal hormone therapy with colorectal cancer risk.
%J British journal of cancer
%V 130
%N 10
%@ 0007-0920
%C Edinburgh
%I Nature Publ. Group
%M DKFZ-2024-00634
%P 1687-1696
%D 2024
%Z #EA:C020#LA:C020# / 2024 Jun;130(10):1687-1696
%X Menopausal hormone therapy (MHT), a common treatment to relieve symptoms of menopause, is associated with a lower risk of colorectal cancer (CRC). To inform CRC risk prediction and MHT risk-benefit assessment, we aimed to evaluate the joint association of a polygenic risk score (PRS) for CRC and MHT on CRC risk.We used data from 28,486 postmenopausal women (11,519 cases and 16,967 controls) of European descent. A PRS based on 141 CRC-associated genetic variants was modeled as a categorical variable in quartiles. Multiplicative interaction between PRS and MHT use was evaluated using logistic regression. Additive interaction was measured using the relative excess risk due to interaction (RERI). 30-year cumulative risks of CRC for 50-year-old women according to MHT use and PRS were calculated.The reduction in odds ratios by MHT use was larger in women within the highest quartile of PRS compared to that in women within the lowest quartile of PRS (p-value = 2.7 × 10-8). At the highest quartile of PRS, the 30-year CRC risk was statistically significantly lower for women taking any MHT than for women not taking any MHT, 3.7
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:38561434
%R 10.1038/s41416-024-02638-2
%U https://inrepo02.dkfz.de/record/289200